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Background
Patients with congestive heart failure (HF) have sympto-
matic improvement with diuretic therapy, although with
time diuretic resistance and renal dysfunction can occur.
Cenderitide (also known as CD-NP), now in clinical trials
in patients with HF, is a Mayo designed chimeric natriure-
tic peptide which, unlike the native natriuretic peptides
(NPs) ANP, BNP and CNP, binds both to guanylyl cyclase
(GC)-B and GC-A with greater affinity for GC-B. Cenderi-
tide thus was designed to mediate more venodilation than
arterial dilation via GC-B and so result in less hypotension
than BNP or ANP, but unlike CNP also possess natriuretic
and diuretic properties via GC-A activation. We tested the
hypothesis that combining cenderitide with furosemide
will produce increased diuresis and natriuresis compared
to furosemide alone without causing excessive hypoten-
sion or renal dysfunction in experimental HF.
Methods
HF was induced in two groups of dogs (n=3 each) by
tachypacing. On day 11 of pacing an acute study was per-
formed under general anesthesia. The left ureter was can-
nulated and the renal artery was equipped with a flow
probe. A continuous inulin infusion was started to mea-
sure glomerular filtration rate (GFR) and after equilibra-
tion a 30-minute baseline clearance (C1) was done. After
that, one group (F+cenderitide) received a 105-minute
cenderitide infusion (100 ng/kg/min), while furosemide (1
mg/kg) was administered over 60 minutes. After a 15-min-
ute lead-in, three 30-minute clearances were done (C2, C3,
C4). For the other group (F) furosemide was administered
together with vehicle instead of cenderitide. Changes from
baseline were compared between groups by unpaired t-
test. Values are mean±SEM. *p<0.05 between groups.
Results
F+cenderitide compared to F resulted in greater increases
in sodium excretion* (+993±123 vs +426±98 µEq/min)
and urine flow* (+8.5±0.8* vs +4.1±0.5 mL/min) in C2
and cumulatively from C2 through C4. GFR, renal blood
flow and renal vascular resistance were similar between
groups. Addition of cenderitide to F reduced right atrial
pressure* but did not result in systemic hypotension.
Conclusion
Adding cenderitide to furosemide significantly increases
natriuresis and diuresis as compared to furosemide
alone. Also, compared to F alone F+cenderitide results
in a greater reduction in cardiac preload without indu-
cing systemic hypotension. These findings suggest that
the combination of F+ cenderitide represents an innova-
tive co-therapy to enhance renal response to diuretics
and to augment preload reduction; therefore, warranting
further studies in human HF.
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